Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;134(9):3953-3959.
doi: 10.1002/lary.31431. Epub 2024 Apr 2.

Safety and Pharmacokinetics of a Ciprofloxacin and Azithromycin Stent for Chronic Rhinosinusitis

Affiliations

Safety and Pharmacokinetics of a Ciprofloxacin and Azithromycin Stent for Chronic Rhinosinusitis

Dong-Jin Lim et al. Laryngoscope. 2024 Sep.

Abstract

Objectives: Previously, we developed a novel double-coated sinus stent containing ciprofloxacin (inner layer) and azithromycin (outer layer) (CASS), but released drug concentrations were found to be insufficient for clinical usage. Our objectives are to improve drug release of CASS and assess safety and pharmacokinetics in rabbits.

Methods: Dip coating was used to create the CASS with 2 mg ciprofloxacin and 5 mg azithromycin. A uniformed double coating was assessed with scanning electron microscopy (SEM), and the release patterns of both drugs and lactate dehydrogenase (LDH) assay were evaluated over 14 days in vitro. Safety, tolerability, and pharmacokinetics of the CASS were tested in rabbits through insertion into the maxillary sinus and evaluated with nasal endoscopy, CT scans, histology, blood counts and chemistries, and in vivo drug release.

Results: SEM confirmed the uniformity of the dual coating of ciprofloxacin and azithromycin, and thickness (μm) was found to be 14.7 ± 2.4 and 28.1 ± 4.6, respectively. The inner coated ciprofloxacin showed a sustained release over 14 days (release %) when soaked in saline solution (day 7, 86.2 ± 3.4 vs. day 14,99.2 ± 5.1). In vivo analysis showed that after 12 days, 78.92 ± 7.67% of CP and 84.12 ± 0.45% of AZ were released into the sinus. There were no significant differences in body weight, white blood cell counts, and radiographic changes before and after CASS placement. No significant histological changes were observed compared to the contralateral control side.

Conclusion: Findings suggest that the CASS is an effective method for delivering therapeutic levels of antibiotics. Further studies are needed to validate efficacy in a preclinical sinusitis model.

Level of evidence: N/A Laryngoscope, 134:3953-3959, 2024.

Keywords: antibiotic stent; antibiotic‐eluting sinus stent; azithromycin; chronic rhinosinusitis; chronic sinusitis; ciprofloxacin; rabbits; sinusitis; topical delivery.

PubMed Disclaimer

Similar articles

Cited by

References

    1. McCormick JP, Thompson HM, Cho DY, Woodworth BA, Grayson JW. Phenotypes in Chronic Rhinosinusitis. Current allergy and asthma reports 2020; 20:20. - PubMed
    1. Cho DY, Grayson JW, Woodworth BA. Unified Airway-Cystic Fibrosis. Otolaryngologic clinics of North America 2023; 56:125–136. - PubMed
    1. McCormick JP, Weeks CG, Rivers NJ et al.. Prevalence of chronic rhinosinusitis in bronchiectasis patients suspected of ciliary dyskinesia. International forum of allergy & rhinology 2019; 9:1430–1435. - PMC - PubMed
    1. Tipirneni KE, Woodworth BA. Medical and Surgical Advancements in the Management of Cystic Fibrosis Chronic Rhinosinusitis. Current otorhinolaryngology reports 2017; 5:24–34. - PMC - PubMed
    1. Illing EA, Woodworth BA. Management of the upper airway in cystic fibrosis. Current opinion in pulmonary medicine 2014; 20:623–631. - PMC - PubMed

MeSH terms

LinkOut - more resources